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ABSTRACT
Vancomycin is used as the antibiotic of choice for severe infection caused by methicillin-resistant Staphylococcus aureus. Increased use of vancomycin 
and the selective pressure has resulted in the emergence of S. aureus with reduced susceptibility to vancomycin and vancomycin-resistant S. aureus. 
This review summarizes the definition, mechanism, clinical significance, and epidemiology of S. aureus with reduced susceptibility to vancomycin. It 
also discusses laboratory methods for detection and treatment options available for these pathogens.
Keywords: Vancomycin, Vancomycin intermediate Staphylococcus aureus, Heteroresistant vancomycin intermediate Staphylococcus aureus, 
Vancomycin resistant Staphylococcus aureus.
INTRODUCTION
Staphylococcus aureus is a major cause of variety of infections in 
health-care setting and community [1]. It causes a variety of clinical 
conditions ranging from asymptomatic colonization to different kinds 
of infections ranging from superficial skin infection to severe infection 
such as sepsis [1]. This pathogen has the unique ability to overcome 
unfavorable conditions such as desiccation, heat, and tolerance to high 
salt concentrations [2]. Resistance to penicillin among S. aureus leads to 
the introduction of methicillin, a semi-synthetic antibiotic. But in 1960s 
appearance of methicillin-resistant S. aureus (MRSA) was reported, 
which was also resistant to carbapenems, cephalosporins and all beta-
lactam antibiotics [3,4]. MRSA over the time has evolved and become 
multidrug resistant hence the rate of mortality and morbidity has 
also increased simultaneously [5]. Due to limited therapeutic options 
vancomycin, a glycopeptide was considered as the drug of choice for 
severe infections due to MRSA.
As the prevalence of MRSA increased worldwide so did the use of 
vancomycin for its treatment, hence it was just a matter of time when 
appearance of S. aureus with reduced susceptibility to vancomycin was 
observed. Vancomycin was approved in 1958 by the US Food and Drug 
Administration. Approximately, after 40 years, in 1997 first case of 
infection by S. aureus with reduced susceptibility to vancomycin was 
documented in Japan [6]. Soon several countries reported similar cases 
of infection due to these mutated pathogens [7-9]. The first case of 
vancomycin-resistant S. aureus (VRSA) was reported from the USA in 
2002 [10]. Several other reports of isolated cases of VRSA infection have 
also been documented over the years [10]. Isolation of heterogeneous 
vancomycin – intermediate S.aureus (hVISA) created further problem 
in the existing crisis of vancomycin treatment as the rate of vancomycin 
treatment failure for these isolates was higher, and also detection of this 
pathogen was difficult [8].
Due to severity and extent of infections caused by S. aureus with lowered 
susceptibility to vancomycin, its isolation is a matter of great concern in 
the medical society. Furthermore, treatment of S. aureus with reduced 
susceptibility to vancomycin is difficult as the alternative treatment is 
expensive and toxic. Hence, rapid identification and proper treatment 
are required to reduce the morbidity and mortality in patients infected 
with these pathogens. This article summarizes the information available 
about S. aureus with reduced susceptibility to vancomycin.
DEFINITIONS
The Clinical and Laboratory Standards Institute (CLSI) recommended 
tests such as broth dilution and agar dilution are used to determine 
minimum inhibitory concentration (MIC) of vancomycin to S. aureus. 
The results are then interpreted, and S. aureus isolates are classified as 
vancomycin-susceptible S. aureus (VSSA), VISA, and VRSA [11].
The definitions of VISA and VRSA are clear as their definitions are 
based on the value of MICs obtained by standard CLSI procedures. 
Heterogeneous VISA (hVISA) definition, on the other hand, is not yet 
clearly defined as a standardized method for determination of its MIC 
is not yet approved.
VISA
In 2006, due to increase in vancomycin treatment failure CLSI revised 
the vancomycin breakpoint. According to recent CLSI guidelines 
MIC of vancomycin was changed from ≤4 µg/ml to ≤2 µg/ml and 
the isolate having this MIC is considered as VSSA while for VISA 
the MIC of vancomycin which was initially 8-16 µg/ml was revised 
to 4-8 µg/ml [12]. Vancomycin MIC results differ based on the methods 
used, therefore CLSI recommended broth macro or microdilution 
should be performed before identifying the isolate as VISA [13].
VRSA
The definition for VRSA generates slight confusion because of different 
cutoff values used in different countries to classify vancomycin 
susceptibility. CLSI has revised the vancomycin MIC for defining VRSA 
according to which instead of a MIC value of ≥32 µg/ml, isolates with a 
MIC of ≥16 µg/ml are considered as VRSA [12]. In the United States and 
several other countries which uses CLSI guidelines, the above MIC value 
is used for classifying VRSA. S. aureus with MIC of vancomycin ≥6 µg/ml 
was described in 2002 in Michigan and in New York in 2004 [11].
Heterogeneous vancomycin-intermediate S. aureus (hVISA)
The definition of hVISA has not been clearly stated as an approved 
standardized method for the detection of this pathogen is not yet 
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available. These isolates have two population of cell; a major part of the 
population is susceptible to vancomycin (MIC ≤2 µg/ml) while a minor 
portion is resistant and has a MIC of 8 µg/ml. The resistant population 
is present in a very low rate of 10−5-10−6 hence they escape detection 
by the routine recommended CLSI method where an inoculum of 
5×104 CFU/well in case of broth dilution or 1×104 CFU/spot in case 
of agar dilution is used [12,14]. Population analysis profile (PAP) is 
used for the detection of hVISA even when S. aureus strains with a 
vancomycin MIC as less as 0.5-1 µg/ml is isolated [15].
Table 1 summarizes classification of S. aureus based on vancomycin MIC 
results obtained by CLSI recommended method.
MECHANISM OF VANCOMYCIN RESISTANCE
Vancomycin acts by binding to D-alanyl-D-alanine (D-ala-D-ala) 
located at C-terminus of late peptidoglycan precursors. It forms a 
stable, noncovalent complex with the cell wall precursor thus making 
it unavailable for cell wall synthesis in S. aureus [16]. The precursors 
for cell wall synthesis are located at the tip of division septum making 
it a major site for cell wall division as the whole cell membrane is not 
involved in the synthesis of S. aureus cell wall [16]. Therefore, it is 
required for vancomycin to diffuse to the tip of division septum so as 
to prevent cell wall synthesis in S. aureus and any mechanism which 
prevents either diffusion or binding of vancomycin results in reduced 
susceptibility to this antibiotic [16].
VISA is believed to arise from hVISA strain after prolonged exposure 
to glycopeptides [13,17]. Increase in the thickness of cell wall has 
been attributed to decreased vancomycin susceptibility. Mutation 
and/or modulation of regulatory systems results in changes in its 
cellular physiology; the cell wall metabolism is enhanced leading 
to increased production of D-ala-D-ala residues. More murein 
monomers and layers of peptidoglycan increase the thickness of cell 
wall. Thus, vancomycin gets entrapped in the outermost layer of cell 
wall and the amount of vancomycin reaching the target site is greatly 
reduced [18]. This mechanism is known as “affinity trapping” [18]. 
The entrapped vancomycin destroys the outer peptidoglycan layer 
and blocks the movement of vancomycin to the inner part of cell wall 
resulting in “clogging phenomenon” [18]. Binding of vancomycin to 
cell wall results in reduced autolytic activity by blocking the activity 
of peptidoglycan hydrolase enzyme (an enzyme responsible for 
shedding the old outer layer of peptidoglycan) [19]. VISA and hVISA 
strains also show a reduced acetate catabolism which results in 
alteration in growth pattern, increased production of intercellular 
adhesion, and change in apoptosis as well as increases antibiotic 
tolerance [19].
Agr operon has been identified as a significant factor which helps 
in reducing vancomycin susceptibility [20]. Isogenic mutation in 
agr group II polymorphism leads to increase in heteroresistance 
to glycopeptides in S. aureus [20]. Genetic makeup of VISA 
includes mutations frequently associated with walKR, vraSR, rpoB, 
yvqF/vraSR genes [11,21]. These genes in most cases are directly 
or indirectly involved with either synthesis or metabolism of cell 
wall in S. aureus [21]. Fig. 1 shows the difference in the cell wall 
thickness of S. aureus ATCC 25923 and Mu50 as seen under electron 
microscope [20].
Mechanism of resistance in VRSA is similar to that of vancomycin-
resistant Enterococci (VRE) [22]. Transposon Tn1546, an 11-kb mobile 
genetic element results in vancomycin resistance [22]. It belongs to 
Tn3 family of transposons and codes 9 polypeptides ORF1 and ORF2 
results in transposition, vanR and vanS responsible for expression 
of vancomycin resistance, vanH and vanA synthesize modified 
peptidoglycan precursors which ends in D-lactate (D-lac), vanX and vanY 
brings about hydrolysis of normal precursors and vanZ, the function 
of which is yet unknown. vanR/vanS regulate inducible expression of 
vanA resistance. In the cytoplasmic domain of vanS, histidine residue is 
present [22]. This histidine residue gets phosphorylated in the presence 
of glycopeptides and in turn activates the aspartate residue present in 
vanR by phosphorylating it too [22]. The phosphorylated vanA binds 
to PRES promoter and activates cotranscription of vanH, vanA, vanX, and 
vanY genes [22]. Binding of vanA to PREG promoter leads to activation 
of vanR and vanS [22]. Vancomycin resistance can result by two 
genetic pathways [22]. Either by plasmid transfer through conjugation 
from Enterococcus species to S. aureus or by transposition through 
insertion of Tn1546 from donor (Enterococcus species) to a resident 
plasmid or chromosome present in the recipient (S. aureus) [22]. Some 
enterococcal plasmid replicate successfully in Staphylococci, but others 
may be lost during cell division (Fig. 2) [22].
The inserted Tn1546 vanA type resistance element produces D-ala-D-
lac in place of D-ala-D-ala which has low affinity for vancomycin thus 









VSSA: Vancomycin susceptible Staphylococcus aureus, MIC: Minimum inhibitory 
concentration, S. aureus: Staphylococcus aureus, VISA: Vancomycin intermediate 
Staphylococcus aureus, VRSA: Vancomycin resistant Staphylococcus aureus
Fig. 1: Difference in cell wall thickness of Staphylococcus aureus 






species to Staphylococcus aureus (Glycopeptide resistant 
Enterococcus) (Adapted from reference 22 with due permission 
from the author)
34
Asian J Pharm Clin Res, Vol 10, Issue 6, 2017, 32-38
 Kumari et al. 
EPIDEMIOLOGY OF S. AUREUS WITH REDUCED SUSCEPTIBILITY 
TO VANCOMYCIN
A 4 months infant from Japan underwent heart surgery in 1996 [6]. 
2 weeks after surgery the surgical site was found to produce purulent 
discharge. Mu50 was isolated from pus culture with vancomycin MIC of 
8 mg/l thereby giving world the first published case of VISA in 1997 [6]. 
hVISA was reported from sputum of a 64 years male patient suffering 
with pneumonia in Japan, 1997 [24]. Soon after isolation of hVISA 
and VISA from Japan, cases of infection due to S. aureus with reduced 
susceptibility to vancomycin was reported from several parts of the 
world [25]. Japan, United States, Australia, France, Brazil, Scotland, 
South Korea, Hong Kong, South Africa, Thailand, and Israel are some of 
the many which have reported infection due to hVISA and VISA [16,26]. 
The rate of VISA varies from 0.04% to 44.9% in Asian countries, in 
America a rate of 0-28.6% has been recorded while a rate of 0.07-31.7% 
has been seen in European countries [25,27,28]. A systematic review 
was conducted by Zhang et al. which included data from Asia, Europe, 
Australia, and America from studies published from 1997 to 2014; 
these studies revealed that the rate of hVISA has gradually increased 
from 4.68% to 7.01% over the years. Similarly, the rate of VISA has also 
increased and the rate of VISA which was initially 2.05% has increased 
to 7.93% at present [27]. According to this study, the rate of VISA was 
3.42% in Asia and 2.75% in Europe/America while hVISA had a rate of 
6.81% in Asia and 5.60% in Europe/America. The first case of hVISA 
from Australia was reported in 2001 and since then increased number of 
hVISA and VISA has been reported from this country. A study conducted 
in Australia showed the rate of VISA isolates to be 1.7% [29]. 33 vanA 
positive VRSA cases have been documented worldwide till date [30]. 
In India, VISA has been reported from Hyderabad, Pondicherry, 
Chandigarh, Mangaluru, and Varanasi [31-35]. Investigators have 
reported 7 VRSA isolates from Hyderabad health-care settings [31]. 
A study conducted in Bhubaneswar reported 28.86% of VRSA and 
45.11% VISA from nosocomial sources while in ICU and NICU the rate 
of VRSA and VISA was 16.80% and 45.17% respectively [28].
LABORATORY DIAGNOSIS
Vancomycin resistance may go undetected in routine antibiotic 
susceptibility testing [25]. Disk diffusion test which used 30 µg 
vancomycin disk was not sensitive for the detection of VISA strains 
and often misclassified VISA as VSSA; it also failed to detect hVISA and 
hence was considered as an inappropriate method for determining 
vancomycin susceptibility [25]. Genetic determinants for detection of 
hVISA and VISA have not yet been defined. Phenotypic methods are 
unable to provide accurate detection of hVISA and in some cases also 
for VISA isolates [25]. However, several methods for screening and 
confirming hVISA and VISA in the clinical specimen are acknowledged.
Colony morphology of hVISA and VISA on conventional agar plate 
may provide subtle information about its presence. Growth kinetics 
of hVISA is supposed to be different from that of standard S. aureus 
culture [16]. hVISA isolates produce small-sized colony or mixed colony 
variants [16]. Different size, pigmentation, hemolysis, and slow growth 
rate of colonies in the same pure culture obtained from the same 
clinical specimen may indicate a possibility of the presence of hVISA or 
VISA variants [16,35]. However, these changes are not diagnostic and 
each different monotype should be tested for vancomycin susceptibility 
with a confirmatory test.
Screening tests for hVISA
hVISA infection has a low proportion of vancomycin intermediate 
population (10−5-10−6). Hence, the standard inoculum (McFarland 0.5 
standard) used for CLSI broth or agar dilution for MIC determination 
fails to detect this subpopulation. Therefore, detection of hVISA requires 
higher inoculum size, longer incubation period or more nutritious 
media to facilitate its growth.
Macro method Etest uses bacterial inoculum equal to 2 McFarland on 
brain heart infusion agar (BHIA) and an incubation period of 48 hrs. 
Both teicoplanin and vancomycin E strips are used on separate plates. 
The test is considered positive if teicoplanin MIC is ≥12 µg/ml or if both 
teicoplanin and vancomycin MIC is ≥8 µg/ml. The result of this test is just 
a cutoff value, and hence the actual MIC value cannot be reported [16]. 
Another screening test is the glycopeptides resistance detection Etest 
(GRD Etest). Here, vancomycin and teicoplanin are present on the 
same E strip and concentration of both ranges from 0.5 to 32 µg/ml. 
Standard inoculum (McFarland 0.5 standard) and Mueller-Hinton Agar 
supplemented with 5% blood is used. The initial result can be read after 
24 hrs and final result after 48 hrs. GRD Etest is considered positive if 
either vancomycin or teicoplanin has a MIC of ≥8 µg/ml [16].
Simplified population analysis described by Hiramatsu et al. involves 
the use of BHIA with 4µg of vancomycin per ml (BHIA-V4) [24]. The 
plate is inoculated with 10 µl of 108 CFU/ml of bacterial suspension. 
Isolates growing at 24 hrs and 48 hrs were considered as potential 
VISA and hVISA, respectively. If the strains produced subcolonies 
which had vancomycin MIC 8 µg/ml and remained resistant for >9 days 
on antibiotic-free medium then such isolates were considered as 
confirmed hVISA [24].
Confirmatory test for hVISA
The reproducibility of simplified population analysis was poor 
and hence Wootton et al. described a modified PAP method [36]. 
Accordingly, BHIA plates are prepared with different concentrations 
of vancomycin (0.5 µg/ml, 1 µg/ml, 2 µg/ml, 2.5 µg/ml and 4 µg/ml). 
Bacterial suspension is prepared using isolates grown in trypticase 
soya broth for 24 hrs. This suspension is then diluted to 10−3 and 10−6 
using saline and used for inoculation of BHIA gradient plates. The 
plates are incubated for 48 hrs at 37°C after which colonies grown on 
the plates are counted. PAP/area under the curve (AUC) is calculated by 
dividing AUC of test organism (MRSA) by corresponding AUC for Mu3. 
If PAP/AUC ratio is <0.9, 0.9-1.3 and >1.3 then the isolate is considered 
as VSSA, hVISA and VISA [37]. Using GraphPad Prism software viable 
count is plotted against vancomycin concentration and AUC is then 
calculated (Fig. 3) [25].
Detection of VISA and VRSA
VISA and VRSA are relatively easy to identify due to the presence of 
recommended and standardized CLSI testing methods [12]. Broth 
macrodilution or agar dilution method can be used for determination 
of vancomycin MIC among test isolates. S. aureus ATCC 29213 and 
Enterococcus faecalis ATCC 29212 are used as the quality control in 
these tests [12]. Other methods such as E test and automated tests such 
Fig. 3: Population analysis curve of vancomycin-intermediate 
Staphylococcus aureus (vancomycin intermediate S. aureus 
[VISA]; Mu50), hetero-VISA (hVISA; Mu3) and “slow VISA” (sVISA, 
a laboratory strain derived from Mu3; Mu3-6R-P). Bars show 
the number of colonies which appeared on each agar plate after 
72 hrs up to 144 hrs of incubation (adapted from reference 
37 with permission from the author)
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as Vitek, Phoenix, and MicroScan rapid panels are used in diagnostic 
laboratories for determination of vancomycin susceptibility [38-40]. 
These methods though are easy, less labor intensive and quick compared 
to the recommended CLSI methods; they have their own drawbacks 
and produces a variable result which is not 100% reproducible [38,39]. 
Hence, vancomycin MIC results determined by any other MIC method 
should always be confirmed by CLSI reference method [12,41]. 
According to CLSI, VISA and VRSA are reported when vancomycin MIC is 
4-8 µg/ml and ≥16 µg/ml, respectively [12,41]. The laboratory methods 
for detection of hVISA, VISA and VRSA is summarized in Table 2.
CLINICAL SIGNIFICANCE OF HVISA, VISA, AND VRSA
Significance of hVISA and VISA in the clinical setting remains unclear. 
Treatment failure in case of infection by these strains is whether due to 
its virulence or level of resistance has yet to be investigated.
β-lactam antibiotics are considered superior to vancomycin by several 
clinicians for treating bacteremia and endocarditis caused by S. aureus. 
Patients with such infection fail vancomycin therapy even if the isolate 
causing the infection is susceptible to the antibiotic when tested [42].
Animal studies have been conducted to ascertain the efficacy of 
vancomycin when used against hVISA and VISA. A rabbit endocarditis 
model harboring Mu50 showed vancomycin treatment failure [16]. The 
presence of high inoculum of hVISA and VISA in vitro models has shown 
decreased activity of vancomycin [43]. A rabbit endocarditis model 
was used which has been infected with clinical strain of MRSA derived 
from an endocarditis patient with vancomycin treatment failure. PAP 
identified the isolate as hVISA which persisted even after vancomycin 
therapy [44].
Several clinical studies around the world suggest treatment failure and 
existence of infection even after vancomycin therapy when this antibiotic 
is used for the treatment of infection caused by hVISA/VISA [16]. 
The first case of VISA reported from Japan showed vancomycin to be 
ineffective in the treatment of infection when used alone and relapse 
of infection occurred. The infant was cured after the therapy had been 
changed from vancomycin to arbekacin and ampicillin sulbactam [8]. 
From the United States, cases of vancomycin treatment failure have 
been documented starting from 1999. Blood which was collected from 
a patient undergoing renal dialysis gave a positive culture of MRSA 
having vancomycin MIC of 2 µg/ml [45]. Later just before patient’s 
death MRSA which was isolated had vancomycin MIC of 8 µg/ml [45]. 
In this incidence, it was not clear if treatment failure was primarily due 
to increasing vancomycin MIC level in the isolate or due to secondary 
adaptation to the antibiotic as a deep-seated MRSA focus present in the 
patient went undetected and was not removed [45]. Two other cases 
were reported from the United States in which patients were infected 
with VISA (MIC 8-16 µg/ml) [46]. These patients had invasive MRSA 
infection which was either persistent or recurrent. In Spain 19 cases 
of MRSA having vancomycin MIC <4 µg/ml were noted [47]. Metallic 
implant was present in 14 of these patients and vancomycin treatment 
failed in 12 of these patients. In the remaining five, only one underwent 
vancomycin treatment failure [47].
About 30 days of vancomycin treatment failed to eradicate MRSA from 
four burns and one osteomyelitis case reported from Brazil [48]. Another 
case of vancomycin treatment failure was recorded in an endocarditis 
patient where MRSA had a vancomycin MIC of 4-8 µg/ml [49]. The 
patient failed to respond to 43 µg/ml trough level of vancomycin but 
responded immediately to linezolid. Long vancomycin exposure of 
about 6-18 weeks, 3-6 month before VISA infection has been suggested 
as an important contributing factor for emergence of VISA [47,49]. 
Studies have shown that this phenotype arises from pre-existing MRSA 
strain which had caused infection months before in the patient [48,50].
In June 2002, the first case of VRSA was reported in a 40 years diabetic 
female patient with chronic renal failure from Michigan, United States. 
The patient had received several courses of antibiotic treatment for 
chronic foot ulcer in the past 15 years with vancomycin being included 
in some of these treatments. In April 2002, before isolation of VRSA 
patient was treated with vancomycin for MRSA bacteremia. VRSA (MIC 
>128 µg/ml) was isolated from a catheter site infection and a swab culture 
from infected foot ulcer. VRSA isolate contained vanA gene and mecA 
gene. The patient was treated with trimethoprim/sulfamethoxazole 
and wound care [46]. Second VRSA case was reported in September 
2002 from a 70 years male patient undergoing treatment for chronic 
plantar ulcer. The patient had multiple lower extremities ulcer and 
osteomyelitis [51]. Before developing VRSA infection, MRSA and VRE 
were frequently isolated from the same site. Main difference in this case 
compared to the first VRSA infection was that the patient had no prior 
exposure to vancomycin except in 1997 when he received vancomycin-
Table 2: Methods for detection of hVISA, VISA and VRSA in laboratory
Media used Inoculum Reference
Detection of hVISA
Screening tests
BHIA+vancomycin 6 µg/ml 10 µl of McFarland 0.5 standard suspension [16]
MHA+vancomycin 5 µg/ml 10 µl of McFarland 0.5 standard suspension [16,59]
MHA+teicoplanin 5 µg/ml 10 µl of McFarland 2 standard suspension [16,59]
Simplified PAP: BHIA+4 µg/ml 10 µl of McFarland 0.5 standard suspension [16,59]
MET: BHIA McFarland 2 standard suspension [16,59]
GRD Etest: MHA with 5% blood McFarland 0.5 standard suspension [16]
Confirmatory test 
Modified PAP: BHIA+vancomycin (0.5 µg/ml, 1 µg/ml, 2 µg/ml, 2.5 µg/ml, 4 µg/ml) Culture incubated in TSB for 24 hrs, then 
diluted to 10−3 and 10−6 and used for 
plating
[37]
Detection of VISA and VRSA
Screening test
Etest McFarland 0.5 standard suspension [16,39,40]
Vancomycin screen agar: BHIA+vancomycin 6 µg/ml 10 µl of McFarland 0.5 standard suspension [12]
Confirmatory test
CLSI recommended broth microdilution McFarland 0.5 standard suspension diluted 
to obtain 5×104 CFU/well
[12]
CLSI recommended agar dilution method McFarland 0.5 standard suspension 
adjusted to obtain 104 CFU/spot of 5-8 mm 
diameter
[12]
BHIA: Brain heart infusion agar, MHA: Mueller hinton agar, MET: Macromethod Etest, GRD Etest: Glycopeptides resistance detection Etest, PAP: Population analysis 
profile, TSB: Trypticase soya broth, VISA: Vancomycin intermediate Staphylococcus aureus, VRSA: Vancomycin resistant Staphylococcus aureus
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impregnated beads for 5 days. This case thus demonstrated that prior 
prolonged vancomycin exposure need not necessarily resulted in 
emergence of VRSA; even frequent use of other antibiotics may create 
selective pressure resulting in a favorable growing site for both MRSA 
and VRE together [51]. This facilitates horizontal vanA gene transfer 
from VRE to MRSA resulting in emergence of VRSA. Till date, 13 
confirmed VRSA cases had been documented from the United States. 
All the patients had a history of prior infection with Enterococcus and 
S. aureus at the same time and at the same site, also most of VRSA 
infected patients had received prior vancomycin treatment [16]. 
Although vancomycin is routinely used in the treatment of MRSA, only 
a few cases of vancomycin resistance has been reported from another 
part of the world [30].
A previous study has shown that the chances of vancomycin treatment 
failure were eleven times more in patients with hVISA bloodstream 
infection than a patient with VSSA bloodstream infection [52]. Patients 
with hVISA and VISA infections have a longer duration of hospital stay, 
recurrent infections, longer treatment regime and while in hVISA the 
response to vancomycin is suboptimal, vancomycin therapy fails in 
cases of VISA infections [53].
TREATMENT OPTIONS AVAILABLE FOR S. AUREUS WITH REDUCED 
SUSCEPTIBILITY TO VANCOMYCIN
Emergence of MRSA itself had narrowed the treatment choices available 
for this pathogen. Emergence of hVISA, VISA and VRSA further created a 
problem in antibiotics selection. Combination therapy with antibiotics 
which have synergistic action should be considered for the effective 
treatment of hVISA, VISA, and VRSA.
hVISA, VISA, and VRSA have been usually isolated from invasive 
infections such as endocarditis, bacteremia, deep-seated abscess, 
osteomyelitis, and prosthetic device related infections. About 31% of 
these cases were treated by the use of antibiotic alone, whereas 69% 




Ampicillin when used in presence of sulbactam for the treatment of 
first case of VISA in Japan in combination with arbekacin was found to 
be a treatment worth consideration for treatment of VISA infection [8]. 
Rifampicin and fusidic acid combination have been used for the 
treatment of complicated MRSA infection. This combination has been 
successfully used in the treatment of MRSA infection where vancomycin 
therapy has failed [50].
Linezolid, a synthetic oxazolidinone inhibits protein synthesis at 50S 
ribosome. It is effectively used in treatment of skin and soft tissue 
infection and also for healthcare-associated pneumonia. Although 
linezolid is bacteriostatic in vitro against S. aureus, it has effectively 
cured several serious infections due to MRSA, hVISA, VISA and 
VRSA [50].
Daptomycin, a lipopeptide class of antibiotic has bactericidal 
activity which is dependent on its concentration [52]. It is effective 
in the treatment of bacteremia, endocarditis and skin and soft 
tissue infections [52]. Mutations in mprF and yycG which leads to 
reduced vancomycin susceptibility in some S. aureus strains has 
also been linked with reduced susceptibility to daptomycin [50]. 
Hence, an association between hVISA and VISA and increased MIC 
of daptomycin has been seen. This association is strain specific and 
not stable [54].
Quinupristin/dalfopristin, a streptogramin is used in the treatment 
of invasive infection where vancomycin treatment has failed as an 
intravenous preparation [50,55].
Tigecycline, a member of tetracycline group of antibiotic shows good in 
vitro activity for some of the VISA strains tested [54].
PROMISING ANTIBIOTICS UNDER DEVELOPMENT
Dalbavancin has good activity against MRSA, hVISA, VISA and VRSA. 
It is also effective for S. aureus resistant tolinezolid and quinupristin/
dalfopristin. Half life of this antibiotic is long and hence 1 dose/week 
is sufficient to maintain serum level [56]. Oritavancin with structure 
almost similar to vancomycin is effective against VISA and VRSA [16]. 
Telavancin has low MIC for MSSA, MRSA and VISA strains but higher 
MIC for VRSA [16].
New cephalosporins are also being tested which shows promising 
results for effective treatment of hVISA and VISA. Ceftaroline in animal 
studies has been useful for the treatment of MRSA infection and was 
found to be equal or superior to vancomycin, linezolid, teicoplanin and 
arbekacin [57]. Doripenem, ranbozolid, telavancin, and iclaprim are 
some of the other promising antibiotics which can be considered in the 
treatment of infection where vancomycin therapy fails [58].
CONCLUSION
The worldwide increase in the rate of multidrug resistance MRSA 
infections, especially in health-care settings, during the past several 
decades has resulted in the frequent use of vancomycin to treat 
such infections. This increased selective pressure has resulted in the 
emergence of MRSA strains with reduced susceptibility to vancomycin 
(VISA) in 1997 and then MRSA strains with high-level resistance to 
vancomycin (VRSA) in 2002. Mutations in determinants that control 
biosynthesis of cell wall and/or mutation in ribosomal gene rpoB results 
in VISA. In case of VRSA, high-level resistance to vancomycin is due to the 
acquisition of copies of transposon Tn1546 from VRE through plasmid. 
VISA strains may develop in vivo during treatment with vancomycin 
VISA and VRSA strains may be detected using CLSI recommended broth 
dilution, agar dilution or Etest. However, detection of hVISA is normally 
difficult. PAP can be used for this purpose. Although VISA strains have 
been isolated from health-care settings, VRSA still is rare.
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